Lantern Pharma
LTRN
32 hedge funds and large institutions have $8.62M invested in Lantern Pharma in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 3 closing their positions.
2,280% more call options, than puts
Call options by funds: $119K | Put options by funds: $5K
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
8% more capital invested
Capital invested by funds: $8M → $8.62M (+$625K)
0% more funds holding
Funds holding: 32 → 32 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.61% less ownership
Funds ownership: 23.17% → 22.56% (-0.61%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWM
Perigon Wealth Management
San Francisco,
California
|
+$103K |
| 2 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$52.7K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$14.7K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$11.5K |
| 5 |
Renaissance Technologies
New York
|
+$6.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$156K |
| 2 |
RAM
Redmond Asset Management
Henrico,
Virginia
|
-$119K |
| 3 |
Two Sigma Investments
New York
|
-$52.8K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$47.1K |
| 5 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$35K |
LTRN Hedge Fund Activity: Q1 2025 in Review
32 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q1 2025, worth a combined $8.62M — up 7.8% from $8M a quarter earlier.
Fund positioning in LTRN was balanced in Q1 2025: 3 funds opened new positions, 3 closed out, 10 added to existing stakes and 5 trimmed.
The largest buyer was Perigon Wealth Management, adding an estimated $103K. The largest seller was Citadel Advisors, exiting entirely with an estimated $156K sold.
- 32 institutional investors held Lantern Pharma (LTRN) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $8.62M of Lantern Pharma stock for Q1 2025, up 7.8% quarter-over-quarter.
- 3 funds opened new Lantern Pharma positions in Q1 2025 and 3 closed out, a net change of 0 holders.
- The largest Lantern Pharma buyer in Q1 2025 was Perigon Wealth Management, an estimated $103K added.
- The largest Lantern Pharma seller in Q1 2025 was Citadel Advisors, an estimated $156K sold.
Based on aggregated 13F filings for Q1 2025.